Michael Halstead - 21 Dec 2021 Form 4 Insider Report for Intra-Cellular Therapies, Inc. (ITCI)

Signature
/s/ Lawrence J. Hineline, Attorney-in-fact
Issuer symbol
ITCI
Transactions as of
21 Dec 2021
Net transactions value
-$5,514,784
Form type
4
Filing time
23 Dec 2021, 18:02:53 UTC
Previous filing
07 Jul 2023
Next filing
11 Jan 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ITCI Common Stock Options Exercise $346,500 +25,000 $13.86* 25,000 21 Dec 2021 Direct
transaction ITCI Common Stock Options Exercise $1,548,725 +88,146 +353% $17.57 113,146 21 Dec 2021 Direct
transaction ITCI Common Stock Options Exercise $1,002,268 +63,717 +56% $15.73 176,863 21 Dec 2021 Direct
transaction ITCI Common Stock Sale $1,099,784 -22,620 -13% $48.62 154,243 21 Dec 2021 Direct F1, F2
transaction ITCI Common Stock Sale $5,012,436 -104,775 -68% $47.84 49,468 21 Dec 2021 Direct F1, F3
transaction ITCI Common Stock Sale $1,707,662 -36,434 -74% $46.87 13,034 21 Dec 2021 Direct F1, F4
transaction ITCI Common Stock Sale $397,481 -8,690 -67% $45.74 4,344 21 Dec 2021 Direct F1, F5
transaction ITCI Common Stock Sale $194,915 -4,344 -100% $44.87 0 21 Dec 2021 Direct F1, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ITCI Stock Option (right to buy) Options Exercise $0 -25,000 -100% $0.000000* 0 21 Dec 2021 Common Stock 25,000 $13.86 Direct F7
transaction ITCI Stock Option (right to buy) Options Exercise $0 -88,146 -100% $0.000000* 0 21 Dec 2021 Common Stock 88,146 $17.57 Direct F7
transaction ITCI Stock Option (right to buy) Options Exercise $0 -63,717 -100% $0.000000* 0 21 Dec 2021 Common Stock 63,717 $15.73 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.30 to $49.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.28 to $48.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.29 to $47.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.25 to $46.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.25 to $45.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F7 All shares underlying this option have vested.